Article

Glaucoma definition continues to be debated

However, IOP remains most important risk factor for blindness

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
Related Content
Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy
May 20th 2025

Q&A: Yasha S. Modi, MD, on retinal nonperfusion in diabetic retinopathy

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA
May 20th 2025

Kriya Therapeutics announces preclinical data for KRIYA-825, gene therapy injection for the treatment of GA

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases
May 19th 2025

Ashvattha reports positive phase 2 data for migaldendranib in retinal diseases

Therini Bio raises $39 million in a Series A extension financing
May 19th 2025

Therini Bio raises $39 million in a Series A extension financing

© 2025 MJH Life Sciences

All rights reserved.